Roche subsidiary Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million, aiming to expand its oncology diagnostics portfolio in molecular residual disease (MRD). The deal includes milestone payments and will bring Saga’s Pathlight tumor-informed MRD platform under the Foundation Medicine umbrella. Foundation said it plans to leverage its Axelios sequencing and Digital LightCycler PCR platforms to help develop decentralized MRD testing for broader global deployment. Pathlight uses whole-genome sequencing plus digital PCR to track structural variants. For MRD-focused developers, the transaction highlights consolidation as Roche moves to scale ultra-sensitive MRD workflows that can support earlier treatment decisions and monitoring strategies.